SCLX

Scilex is a commercial-stage non-opioid pain company (ZTlido, GLOPERBA, ELYXYB) with a late-stage pipeline (SEMDEXA Phase 3, SP-103, SP-104), but the balance sheet is the whole story and it is broken. FY2025 revenue fell 46.5% to $30.3M — reversing years of growth (peak $56.6M in FY2024) — while the company posted a -$374M net loss and -$346M operating loss. Stockholders' equity is negative $208M against a -$922M accumulated deficit, so the equity is a residual claim on a company whose liabilities ($577M) exceed its assets ($365M). This is a textbook 'avoid': you cannot value equity on fundamentals when book equity is deeply negative and the company is effectively insolvent.

Liquidity is the acute risk. Cash is just $4.96M against $484M of current liabilities and only $38.4M of current assets — a working-capital hole of roughly $446M, with $83.3M of debt classified current (up 138.7%). The MD&A's very first forward-looking risk is 'our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market,' and management executed a 1-for-35 reverse split in April 2025 — a classic move to hold a minimum bid price, not a sign of health. Shares outstanding collapsed 96.5% to 8.49M purely from that split, which is why the -$36.48 diluted EPS and $7.81 price look superficially normal; the underlying dilution/distress is severe. Note the reported 415.8% gross margin and -1,236% net margin are artifacts — gross profit ($126M) exceeding revenue ($30.3M) signals non-operating/one-off accounting items, so the headline ratios are not meaningful and reduce confidence in a clean read.